Apple's amazing quarter, MannKind rebounds, Zillow zipping higher
Time for your daily dose of trending tickers, the stocks that you're tracking as measured by Yahoo Finance ticker searches:
After getting mashed on Friday, MannKind (MNKD) shares soaring today after the FDA finally approved its inhaled insulin drug Affreza. The drug is a powder that is inhaled through the lungs and is reportedly faster acting than injected insulin treatments. It's been a long road for Affrezza, after eight years of trials and obstacles, and two prior FDA rejections. Affreza will be used to treat type one and type two diabetes, but will carry the strongest advisory on its box warning due to pulmonary risks.
Apple (AAPL) shares are higher and making the list not for any breaking news but on the basis of a phenomenal 2nd quarter. Shares are up 20% over the last 3 months, as the company slowly unveils its strategy for competing in the cloud-based world. No, we still don't have a television set, iPhone 6 or iWatch but the Yosemite OS shores up some glaring deficiencies and hints at a coming deluge of devices and services designed to keep users happily trapped in the iTunes ecosystem for years to come. Apple shares are up 30% since the end of January and just 10% off record highs set way back in 2012.
And finally, Zillow (Z). The online real estate database is up more than 3% on news that MLS-Listings has joined the platform. The partnership requires any data from the multiple listing service to automatically update on Zillow every 15 minutes, ensuring the most current data. It all comes as welcome news to savvy consumers who seem to be buying houses at an increased rate. Existing home sales reported earlier today made their biggest month-over-month jump in four years -- surging 6.1% percent in May.
More from Breakout:
'Common sense' says look out for a market drop
